Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy Patients.

Détails

ID Serval
serval:BIB_82D785D8B1EE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy Patients.
Périodique
Ophthalmology. Retina
Auteur⸱e⸱s
Feenstra HMA, van Dijk EHC, van Rijssen T.J., Tsonaka R., Diederen RMH, Schlingemann R.O., Hoyng C.B., Boon CJF
ISSN
2468-6530 (Electronic)
ISSN-L
2468-6530
Statut éditorial
Publié
Date de publication
10/2022
Peer-reviewed
Oui
Volume
6
Numéro
10
Pages
930-938
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
To compare the efficacy and safety of crossover treatment to half-dose photodynamic therapy (PDT) and eplerenone treatment after the failure of primary treatment in patients with chronic central serous chorioretinopathy (cCSC).
Multicenter crossover clinical trial.
At 3 months after the baseline visit of the SPECTRA (Half-Dose Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy) randomized controlled trial, either half-dose PDT or eplerenone treatment was evaluated for each patient, and patients who still demonstrated subretinal fluid (SRF) were included in the current study, the SPECS (Central Serous Chorioretinopathy Treated with Half-Dose PDT or Eplerenone Crossover Study) trial.
At the baseline visits for the current SPECS trial, crossover treatment was performed for patients who still demonstrated SRF. These patients received either half-dose PDT or oral eplerenone for 12 weeks. Both anatomic and functional parameters were evaluated 3 months after crossover treatment.
Complete resolution of SRF on OCT.
Forty-nine patients were included in the SPECS trial (38 received primary eplerenone treatment; 11 received half-dose PDT). At 3 months after crossover treatment, 32 of 37 (86.5%) in the crossover to half-dose PDT group and 2 of 9 (22.2%) in the crossover to eplerenone group had complete SRF resolution (P = 0.030). The mean foveal sensitivity increased significantly more in the crossover to half-dose PDT group (mean, +3.08 dB) compared with the crossover to eplerenone group (mean, -0.27 dB; P = 0.009).
Patients with cCSC with the persistence of SRF after primary eplerenone treatment can benefit from half-dose PDT, which can induce a relatively fast and complete SRF resolution, along with an improvement in foveal sensitivity.
Mots-clé
Central Serous Chorioretinopathy/diagnosis, Central Serous Chorioretinopathy/drug therapy, Chronic Disease, Cross-Over Studies, Eplerenone/therapeutic use, Fluorescein Angiography, Humans, Photochemotherapy, Photosensitizing Agents/therapeutic use, Tomography, Optical Coherence, Verteporfin/therapeutic use, Visual Acuity, Central serous chorioretinopathy, Eplerenone, Half-dose photodynamic therapy, Mineralocorticoid receptor agonist
Pubmed
Web of science
Création de la notice
01/02/2023 8:55
Dernière modification de la notice
26/02/2024 17:44
Données d'usage